RUNX1 and leukemia: As a whole, their results revealed that there was at least one neo-epitope in 88% of the leukemias, in 78% of the CNS, and in 90% of the solid tumors; 69.6% of the neo-epitopes were identified for the leukemias that were characterized by the ETV6-RUNX1 fusion.